Meta AnalysisID 5635
中药注射剂（艾迪注射液）控制恶性胸腔积液的证据框架：一项聚类系统评价与Meta分析
CRD42022331859
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Aidi Injection in adjuvant chemotherapy for gastric cancer.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5635
- Evidence Id
- 14193
- Core Evidence Id
- 14193
- Source Meta Analysis Id
- 5618
- Herb2 Meta Analysis Id
- HBMA005618
- Crd Id
- CRD42022331859
- Title
- The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: a clustered systematic review and meta-analysis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Aidi Injection in adjuvant chemotherapy for gastric cancer.
- Study Type Included
- Randomized controlled trials (RCTs) will be included.
- Condition Being Studied
- Gastric cancer is a common type of malignant tumor with relatively poor prognosis and presents a serious threat to global health. Although the development of gastric cancer diagnosis and treatment technology in recent years has prolonged the overall survival (OS) of patients to some extent, However, the detection rate is low because of the lack of specific signs of early gastric cancer, and therefore, most patients were diagnosed with advanced stage at the first diagnosis and often died due to rapid multi-organ metastasis, with a 5-year survival rate of only 5%. Hence, they are forced to accept the systemic chemotherapy, radiotherapy, or chemoradiotherapy. However, radiochemotherapy-related toxicity presents a significant obstacle to improving long-term survival and quality of life. Therefore, It is the key problem how to alleviate the toxicity and improve the clinical efficacy.
- Participant
- The inclusion criteria for the studies were as follows: (1) The patients had Gastric cancer and were diagnosed using thhistopathological and cytological diagnostic criteria and the TNM staging system. (2) There were randomized controlled trials (RCTs). (3) The experimental group was Aidi injection plus chemotherapy and control group was chemotherapy which types were not limited. (4) Patients prior to being included in the study had not received the radiotherapy, targeted therapy, other chemotherapy or Chinese herbs. (5) We analyzed the clinical efficacy using tumor responses, survival, QOL, and antitumor immunity, and the ADRs using hematotoxicity, gastrointestinal toxicity, hepatorenal toxicity, neurotoxicity, alopecia and oral mucositis. The study design was randomized controlled trial (RCT). (6) None of the restrictions were set on the Karnofsky Performance Status (KPS) score, anticipated survival time (AST), treatment process (primary treatment, PT/retreatment, and RT), age of patients, usages of Aidi and Chemotherapy regimen, or follow-up.
- Animal
- Human Disease Modelled
- Intervention
- Chemotherapy regimen was the main intervention
- Comparator Control
- The experimental group was Aidi injection plus chemotherapy and control group was chemotherapy which types were not limited.
- Main Outcome
- Tumor responses, Anticipated survival time (AST), QOL Measures of effect we used odds ratios (ORs), standardized mean difference (SMD), and 95% confidence interval (CI) to express outcomes, and p<0.05 was considered statistically significant. Tumor response, KPS improvement and adverse reactions were considered dichotomous variables and presented as odds ratio (OR) with 95% confidence interval (95% CI). Immune functions were continuous variables and presented as mean difference (MD) with 95% CI.
- Outcome Measure
- Additional Outcome
- Karnofsky Performance Status (KPS) score, treatment process (primary treatment, ADRs, PT/retreatment, and RT), age of patients, usages of Aidi and Chemotherapy regimen.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Pleural Effusion, Malignant
- Contact
- Jun Huang [email protected]
- Organisational Affiliation
- Department of Pharmacy, Affiliated Hospital of Zunyi Medical University
- Funding Source
- Affiliated Hospital of Zunyi Medical University
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-23
- Registration Date
- 2022-06-03
- Anticipated Start Date
- 2022-02-01
- Anticipated Completion Date
- 2022-10-31
- Title Cn
- 中药注射剂（艾迪注射液）控制恶性胸腔积液的证据框架：一项聚类系统评价与Meta分析
- Title En
- The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: a clustered systematic review and meta-analysis
- Bilingual Status
- complete